Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Osimertinib Plus Savolitinib Exhibits Clinically Meaningful ORR vs Osimertinib in EGFR+ NSCLC

September 9th 2024

The combination of osimertinib/savolitinib demonstrated a significant improvement in ORR in de novo MET-aberrant, EGFR-mutant advanced NSCLC.

Vimseltinib Shows Efficacy in Rare Tenosynovial Giant Cell Tumors

September 9th 2024

R. Lor Randall, MD, FACS, highlights key findings from the pivotal MOTION trial of vimseltinib in patients with TGCT.

Novel Perioperative Combinations Show Efficacy in Resectable NSCLC

September 8th 2024

Several novel combinations yielded high pCR and mPR rates in patients with resectable non–small cell lung cancer, according to data from the 2024 IASLC conference.

Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in PD-L1+ Advanced NSCLC

September 8th 2024

Ivonescimab produced a significant improvement in PFS vs pembrolizumab as frontline therapy in patients with PD-L1–positive advanced NSCLC.

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology

September 6th 2024

The NCCN Clinical Practice Guidelines in Oncology now list denileukin diftitox as an appropriate option for patients with cutaneous T-cell lymphoma.

Vorasidenib Breaks Through as the First Systemic Therapy for Select Patients With Glioma

September 6th 2024

Seema Nagpal, MD, discusses the significance of the FDA approval of vorasidenib for adult and pediatric patients with IDH1/2-mutant glioma.

Talazoparib Plus Pacritinib Aims to Improve the Limitations of Second-Line Therapy in MPNs

September 5th 2024

Peter Abdelmessieh, DO, MSC, discusses the phase 1 trial testing the combination of talazoparib and pacritinib in myeloproliferative neoplasms.

Medicare Drug Price Negotiation Program Will Result in Financial Burdens for Community Oncology Practices

September 5th 2024

Debra Patt, MD, PhD, MBA, FASCO, highlights considerations with financial burdens that will be placed on community providers and oncology practices.

Vice President of COA Unpacks Effects of the Medicare Drug Price Negotiation Program in the Community

September 3rd 2024

Debra Patt, MD, PhD, MBA, FASCO, details how the Medicare Drug Price Negotiation Program Draft Guidance will affect community oncologists and practices.

Targeted Therapy, Vaccines, and Second-Generation Checkpoint Inhibitors Seek to Redefine mCRC Treatment

September 1st 2024

Arvind Dasari, MD, MS, discusses considerations and challenges associated with treating patients in the later-line colorectal cancer setting.

Nivolumab Plus Neoadjuvant Chemoradiation Fails to Enhance pCR Rate in Esophageal/GEJ Adenocarcinoma

August 31st 2024

Jennifer R. Eads, MD, explains the relevance of negative results from the ECOG-ACRIN EA2174 trial in esophageal/gastroesophageal junction adenocarcinoma.

Dr Chase on the FDA Approval of Dostarlimab Plus Chemotherapy in Endometrial Cancer

August 30th 2024

Dana M. Chase, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Is the Current Framework of Academic Oncology Failing Community Providers?

August 30th 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

Fruquintinib Represents a Novel Therapeutic Approach in Advanced mCRC

August 30th 2024

Arvind Dasari, MD, MS, discusses fruquintinib as later-line treatment for patients with advanced metastatic colorectal cancer.

Stepwise Approach Helps Ease the Integration of BiTEs Into Community Cancer Centers

August 29th 2024

Courtney Van Houzen, PharmD, discusses key factors to be aware of when implementing bispecific T-cell engager programs into the community setting.

RELATIVITY-048 Data Highlight Potential of Triplet ICI Regimen for Advanced Melanoma

August 29th 2024

Ankit Mangla, MD, expands on early data from the RELATIVITY-048 trial evaluating a triplet immunotherapy regimen in untreated advanced melanoma

Novel Targets Facilitate Treatment Advances and Spur Further Questions in Endometrial Cancer

August 28th 2024

Ritu Salani, MD, discusses the development of ADCs, the potential role of selinexor, and the use of PARP inhibitors across endometrial cancer subsets.

FDA Grants Priority Review to Mirdametinib for NF1-Associated Plexiform Neurofibromas

August 28th 2024

Priority review was granted to the NDA seeking approval of mirdametinib in patients with neurofibromatosis type 1–associated plexiform neurofibromas.

FDA Grants Fast Track Designation to BGB-16673 in Previously Treated CLL/SLL

August 26th 2024

BGB-16673 has received FDA fast track designation for relapsed or refractory CLL or SLL following 2 or more prior lines of therapy.

EU Greenlights Odronextamab for R/R Follicular Lymphoma and DLBCL

August 26th 2024

The European Commission approved odronextamab for patients with relapsed/refractory FL or DLBCL who have received at least 2 prior lines of therapy.